Additionally, in our in vivo study using the murine CDI model, fidaxomicin exposure resulted in the downregulation of RNA expression of proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), and fidaxomicin monotherapy and combination therapy groups showed similar RNA expression levels at day 8 (Fig. 5C). The gene discussed is TNFSF13B; the disease is clostridium difficile infection.